Implementing and Personalizing Best-In-Class Opioid-sparing Pain Management for Major Inpatient Surgeries in Children
Project Number1U01HD116257-01
Contact PI/Project LeaderSADHASIVAM, SENTHILKUMAR Other PIs
Awardee OrganizationUNIVERSITY OF PITTSBURGH AT PITTSBURGH
Description
Abstract Text
PROJECT SUMMARY: The multicenter PRECISE Analgesia (Prospective Randomized Evaluation of Analgesia
for Cardiac and Idiopathic Scoliosis Spine Fusion Elective Surgery in Children) trials will a) implement and in-
vestigate the efficacy and safety of multidose methadone-based standardized enhanced recovery after surgery
(ERAS) protocol, and b) develop personalized ERAS protocols including precision methadone and oxycodone
dosing and personalized analgesia for the safe and effective opioid-sparing management of surgical pain after
posterior spine fusion (PSF) and cardiac surgery (CS) in children. PSF and CS are both extremely painful sur-
geries in children requiring long hospital stays and high opioid use associated with adverse effects (AEs), high
incidence of opioid dependence (OD), and chronic post-surgical pain (CPSP). Post-discharge prescribed oxyco-
done is used for >1-2 weeks, and opioid dependence occurs within 5 days in children. 20-50% of children develop
CPSP, largely due to severe uncontrolled acute surgical pain, contributing to life-long risks for opioid use/misuse
and the ongoing opioid epidemic. There is an urgent need for safe, effective opioid-sparing analgesia as well as
proactive risk predictions and personalized analgesia to provide best-in-class immediate surgical pain relief while
minimizing the risk of opioid-induced respiratory depression (RD), sedation, postoperative nausea and vomiting
(PONV), CPSP and persistent opioid use/misuse. Recently, we showed that a methadone- based standardized
ERAS protocol shortened hospital stays (2-4 days), reduced prescribed opioid use (5-7 vs. 7-18 days), and the
risks of CPSP. Despite this improvement, with standardized methadone ERAS, 30-40% of children still experi-
enced uncontrolled severe pain, PONV, and sedation from methadone and oxycodone. Our preliminary data
show that CYP2B6 and ORM1 genotypes and alpha acid glycoprotein (AAG) contribute to the variation in phar-
macokinetics (PK), analgesia, and adverse outcomes. Our preliminary data in children undergoing CS with car-
dio-pulmonary bypass (CPB) reveal opioid-sparing and safe postoperative analgesia with methadone. We will
now study the effect of CPB on intraoperative methadone dosing with robust PK modeling to enable precision
methadone dosing for the first time in children. Our expert multidisciplinary team will enroll a total of 1000
children to conduct two parallel randomized clinical trials for PSF (500 children 12-<18 yrs from 4 clinical sites)
and CS (500 children 1 month-10 yrs from 5 clinical sites). Specifically, we will 1. Conduct two randomized clinical
trials in PSF and CS to compare acute pain relief, opioid-sparing efficacy, and safety of standardized periopera-
tive multidose methadone-based ERAS vs. standard-of-care non-methadone-based analgesia. 2. Develop pre-
cision methadone dosing based on age, CYP2B6 and ORM1 variants, AAG, and CPB, and 3. Identify patient
profiles that predict benefit from the assigned analgesia protocol to optimize clinical outcomes. Overall Impact:
Implementation of evidence-based standardized methadone-based ERAS pain management and individualized
risk prediction will maximize acute surgical pain relief while minimizing opioid use and AEs in millions of children.
Public Health Relevance Statement
Project Narrative
Each year, >5 million American children undergo surgeries including major and painful cardiac surgeries and
spine fusion surgeries. More than 50% of these children experience uncontrolled severe acute surgical pain,
significant opioid-related adverse outcomes including respiratory depression, persistent opioid use/misuse, opi-
oid dependence, overdoses, and deaths, and chronic persistent surgical pain. Implementation of evidence-based
standardized perioperative methadone-based multimodal acute surgical pain management in this clinical trial,
and proactive and personalized risk identification will maximize acute surgical pain relief while minimizing opioid
use, serious opioid-related adverse outcomes, and transition of acute surgical pain to chronic surgical pain in
millions of children undergoing major and painful surgeries each year.
NIH Spending Category
No NIH Spending Category available.
Project Terms
ABCB1 geneAbsence of pain sensationAcidsAcuteAcute PainAdolescentAdverse effectsAgeAmericanBinding ProteinsCYP2B6 geneCYP2D6 geneCardiacCardiac Surgery proceduresCardiopulmonary BypassCessation of lifeChildChronicClinicalClinical TrialsDataDependenceDoseDrug KineticsEnrollmentEpigenetic ProcessEvaluationFutureGenesGeneticGenetic VariationGenotypeGlycoproteinsGoalsHeritabilityIdiopathic scoliosisIncidenceIndividualLength of StayLifeMethadoneMethylationMorbidity - disease rateN-MethylaspartateOperative Surgical ProceduresOpiate AddictionOpioidOutcomeOverdoseOxycodonePainPain managementPerioperativePostoperative Nausea and VomitingPostoperative PainPostoperative PeriodProtocols documentationPsychological FactorsRandomizedReportingRiskSafetySedation procedureSpecific qualifier valueSpinal FusionStandardizationSurgical ManagementTimeVariantVentilatory Depressionadverse outcomeantagonistclinical research siteevidence baseexperiencegenetic variantimprovedinpatient surgerymorphine equivalentmultidisciplinarymultimodalityopioid epidemicopioid sparingopioid usepain chronificationpain reliefpersonalized risk predictionpharmacokinetic modelpostoperative recoveryprescription opioidprofiles in patientsprospectivepsychologicrandomized, clinical trialsrisk minimizationrisk predictionrisk prediction modelstandard of caresurgical pain
Eunice Kennedy Shriver National Institute of Child Health and Human Development
CFDA Code
853
DUNS Number
004514360
UEI
MKAGLD59JRL1
Project Start Date
05-September-2024
Project End Date
31-August-2029
Budget Start Date
05-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$3,404,830
Direct Costs
$2,258,600
Indirect Costs
$1,146,230
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$3,404,830
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1U01HD116257-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01HD116257-01
Patents
No Patents information available for 1U01HD116257-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01HD116257-01
Clinical Studies
No Clinical Studies information available for 1U01HD116257-01
News and More
Related News Releases
No news release information available for 1U01HD116257-01
History
No Historical information available for 1U01HD116257-01
Similar Projects
No Similar Projects information available for 1U01HD116257-01